New Shot-Based myeloma treatment shows promise in early trial

This study tests a new way to give the drug isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The treatment combines isatuximab with three standard chemotherapy drugs (bortezomib, lenalidomide, and dexamethasone). The goal is to see how well this combination controls the disease and how convenient it is for patients. The study involves 74 adults aged 65 and older across multiple centers in France.